<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00205283</url>
  </required_header>
  <id_info>
    <org_study_id>2002-212</org_study_id>
    <nct_id>NCT00205283</nct_id>
  </id_info>
  <brief_title>Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection</brief_title>
  <official_title>Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agouron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of prospective drug level monitoring and
      dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group of
      HIV-infected patients who have achieved virologic success while receiving a nelfinavir
      containing highly active antiretroviral therapy (HAART) regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">August 1, 2005</completion_date>
  <primary_completion_date type="Actual">August 1, 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Nelfinavir pharmacokinetics</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of nelfinavir and M8 pharmacokinetics on virologic response</measure>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antiretroviral naive or currently taking a nelfinavir containing HAART regimen where
             nelfinavir is the first protease inhibitor

          -  Patients willing to comply with the protocol

          -  Age greater than or equal to 18 years

          -  Virologically successful if already on an established regimen

        Exclusion Criteria:

          -  Prior use of a protease inhibitor exclusive of nelfinavir

          -  Required use or concomitant use of drugs that may interact with or are contraindicated
             with nelfinavir

          -  Use of immunomodulators or vaccines for HIV disease

          -  Intercurrent illness at the time of enrollment that, in the clinician's judgement,
             could influence the HIV RNA concentration

          -  Baseline ALT levels greater than five times the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Andrew Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

